Kodiak Sciences downgraded by JP Morgan
$KOD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JP Morgan downgraded Kodiak Sciences from Neutral to Underweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/5/2024 | $3.00 | Neutral | H.C. Wainwright |
| 12/11/2023 | $2.00 | Sell | Goldman |
| 11/17/2023 | $7.00 → $12.00 | Equal Weight → Overweight | CapitalOne |
| 7/27/2023 | $15.00 → $4.00 | Buy → Neutral | UBS |
| 7/25/2023 | Buy → Neutral | Chardan Capital Markets | |
| 7/25/2023 | Neutral → Underweight | JP Morgan | |
| 7/24/2023 | Buy → Hold | Jefferies | |
| 7/24/2023 | $7.00 | Overweight → Equal Weight | CapitalOne |
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio
PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00
Goldman resumed coverage of Kodiak Sciences with a rating of Sell and set a new price target of $2.00
CapitalOne upgraded Kodiak Sciences from Equal Weight to Overweight and set a new price target of $12.00 from $7.00 previously
PALO ALTO, Calif., Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation provide a comprehensive and up-to-date overview of where we stand today and where we are going – this is what I call 'Kodiak 2.0'. The video webcast includes scientific, clinical and commercial perspectives from key retina opinion leaders Dr. David Brown and Dr. Charles Wykoff. We encourage you to study these materials which are
PALO ALTO, Calif., Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings. Jefferies London Healthcare Conference, November 21, 2024, 9:00 AM GMT (1:00 AM PT), London, UK7th Annual Evercore ISI HealthCONx Conference, December 3, 2024, 2:35 PM ET (11:35 AM PT), Coral Gables, FloridaA live webcast of both presentations will be available on the "Events and Pr
PALO ALTO, Calif., Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois. Presentation and Panel details are below: Presentation Title: Update on Antibody Biopolymer Conjugates: Optimizing Immediacy and DurabilityTime: 3:30 PM CTPresenter: Mark Barakat, M.D., FASRS, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine – Phoenix; Founder and Director of Research,
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(1.07) by 23.36 percent.
Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer. GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month dosing for all patients. The GLOW2 study design mirrors the successful GLOW1 study in which tarcocimab-treated patients, over the 48-week study du
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data highlight multiple ascending dose safety, bioactivity and durability in treatment-naïve and treatment-experienced patients and next steps of Phase 3 development for KSI-501 and Phase 1b development for KSI-101.Novel small molecules and protein therapeutics highlight potential for targeted, high drug-antibody-ratio (DAR) conjugates built on Kodiak's ABC Platform.PALO ALTO, Calif., May 2, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, devel
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr
SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive